People suffering from migraines will soon have access to pain relief in the form of a nasal spray. The U.S. Food and Drug Administration (FDA) has approved the first calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray intended to treat migraines in adults. "Zavzpret underscores Pfizer’s commitment to delivering an additional treatment option to help people with migraine gain relief and get back to their daily lives." (Photo by: BSIP/Universal Images Group via Getty Images)Pfizer touts quick pain relief as the biggest benefit of Zavzpret. The medication is also said to eliminate moderate to severe headache pain within two hours, with effects lasting for up to 48 hours.

Source: Fox News March 11, 2023 17:23 UTC